The proposed order would reclassify sunlamp products from Class 1 to Class 2 medical devices and require the devices undergo premarket FDA review.
The incidence of pediatric melanoma has increased by about 2% per year since 1973.
One-in-four melanoma survivors report they do not wear sunscreen when going outside on a warm sunny day.
Researchers suggest cancer events be routinely reported in future trials of the antiarrythmia drug and call for additional observational studies.
The depression and anxiety medication duloxetine is effective in reducing pain in patients with chemotherapy-induced peripheral neuropathy.
Multitarget stool DNA-based test has a 98% sensitivity for detecting colorectal cancer.
The FDA has approved protein-bound paclitaxel as a treatment for patients with non-small cell lung cancer who are not candidates for surgery or radiation.
A patient has elevated creatine and fasciculations. Could an electrolyte imbalance be the cause?
Choline C 11 Injection, a PET scan imaging agent, is now available for men with elevated PSA levels after earlier treatment for prostate cancer.
Lack of cancer expertise, continuity of care cited as barriers to receiving follow-up cancer care from primary care providers.
HPV DNA testing at baseline predicted progression to cervical intraepithelial neoplasia grade 3 at 18-year follow-up more accurately than Pap smear.
Melanoma risk increases with each additional session of sunbed use per year, and for those whose first use was before age 35 years.
Recommending fecal occult blood testing as an alternative to colonoscopy could increase colorectal cancer screening compliance.
A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose.
Based on the evidence, the U.S. Preventive Services Task Force gave a grade D recommendation against PSA-based screening for men in the general U.S. population, regardless of age.
Counseling moderately increases the use of sun-protective behaviors in 10- to 24-year-old patients who are at high risk for skin cancer.
The FDA is notifying healthcare providers about an increased risk for second primary malignancies in patients with newly-diagnosed multiple myeloma who received Revlimid (lenalidomide capsules; Celgene).
Brachytherapy is associated with more complications, but no difference in overall survival compared with whole-breast irradiation after lumpectomy in older women with invasive breast cancer.
Women with extremely dense breasts and those with a first-degree relative with breast cancer may benefit from biennial mammography starting at age 40 years.
Additional surveillance and methodology are needed to assess the impact of HPV vaccines on disease incidence going forward.
Ongoing use of combined hormone therapy for 10 years or longer doubled the risk for breast cancer.
Regular aspirin use significantly the reduced risk for cancer, metastasis and cancer mortality, findings from three analyses published in Lancet and Lancet Oncology indicate.
Women who develop problematic hot flashes after breast cancer treatment, a contraindication for hormone replacement therapy, experienced significant improvement in quality of life after receiving behavioral therapy.
The FDA is warning health care professionals about a counterfeit version of Avastin 400mg/16mL, which may have been purchased and used by some medical practices in the United States.
The FDA expanded indications for imatinib mesylate tablets (Gleevec, Novartis) to include patients who have had CD117-positive gastrointestinal stromal tumors surgically removed.
Type 2 diabetes has a greater effect on cancer outcomes than on the risk of incident cancer
Highest risk seen for patients with previous diagnosis of cutaneous melanoma
Fentanyl nasal spray is indicated for breakthrough pain in opioid-tolerant patients who are already receiving and tolerant to continuous opioid therapy for underlying persistent cancer pain.
More than half adults older than 75 years are still screened for prostate, colorectal, breast and cervical cancers, with clinician recommendation for specific tests among the greatest predictors of screening.
Women with low-grade cancer tumors who increased their starch intake 5-g per day upped their recurrence risk 3%.